Portal de investigación
EVALUACIÓN DE LA USABILIDAD DE UNA APLICACIÓN MÓVIL EN PACIENTES DIAGNOSTICADOS DE MIELOMA MÚLTIPLE.
Datos básicos
- Protocolo:
- SEFH-APP-MM
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2017
- Año de finalización:
- 2018
Objetivos del proyecto
Observaciones: Estado Comité: ACTIVO
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[[Translated article]]Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus Between Hospital Dermatologists and Pharmacists.
Herranz-Pinto P; (...); Tortajada Goitia B
Practice Guideline. 10.1016/j.ad.2023.07.008. 2023
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Checklist for the pharmaceutical care of patients with interstitial lung disease (CheckEPID): A Delphi-based consensus.
Calvin-Lamas, Marta; (...); Ventayol Bosch, Pere
Article. 10.1016/j.farma.2023.09.004. 2023
2022 update of the indicators for quality of care and pharmaceutical care for people living with human immunodeficiency virus.
Martin Conde MT; (...); Morillo-Verdugo, Ramon
Article. 10.1016/j.farma.2023.04.008. 2023
2022 update of the indicators for quality of care and pharmaceutical care for people living with human immunodeficiency virus.
Martin, Maria Teresa; (...); Morillo-Verdugo, Ramon
Article. 10.1016/j.farma.2023.01.007. 2023
A Qualitative Tool to Guide in the Interpretation of the Numerical Rating Scale for Pruritus Intensity in Patients with Atopic Dermatitis.
Figueras I; (...); Ortiz de Frutos FJ
Article. 10.2340/actadv.v104.18255. 2024
Administration of Subcutaneous Furosemide in Elastomeric Pump vs. Oral Solution for the Treatment of Diuretic Refractory Congestion.
Lopez-Vilella, Raquel; (...); Almenar Bonet, Luis
Article. 10.1007/s40292-021-00476-4. 2021
Analysis of the situation of pharmaceutical care for patients with immune-mediated inflammatory diseases before and after the COVID-19 pandemic.
Lopez Sanchez, Piedad; (...); Monte Boquet, Emilio
Article. 10.1016/j.farma.2024.10.001. 2024
ANALYSIS OF THE USE OF MOBILE APPLICATIONS IN PATIENTS WITH HAEMOPHILIA AFTER TWO YEARS OF FOLLOW-UP
Megias Vericat, J. E.; (...); Bonanad Boix, S.
Meeting Abstract. 2019
Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
BIOSIMILARS IMPACT ON THE RHEUMATOID ARTHRITIS TREATMENT: A COST-EFFECTIVENESS MODEL FROM SPANISH NATIONAL HEALTHCARE SYSTEM PERSPECTIVE
Fernandez Santos, J. M.; (...); Borras Blasco, J.
Meeting Abstract. 2022
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
CLINICAL VALIDATION OF THE SPECIFIC POPULATION MODEL OF FACTOR VIII/FVW PLASMA USING WAPPS-HEMO
Megias Vericat, J. E.; (...); Poveda, A. J. L.
Meeting Abstract. 2019
Collaborative model of home delivery program in haemophilia through an association of patients
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain
Monte-Boquet, Emilio; (...); Sellas, Agusti
Article. 10.1016/j.reuma.2022.12.001. 2023
COST-EFFECTIVENESS ANALYSIS OF BIOSIMILARS BASED TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE CROHN DISEASE IN SPAIN
Fernandez Santos, J. M.; (...); Merino-Bohorquez, V
Meeting Abstract. 2022
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Checklist for Pharmaceutical Care of the Patient with interstitial lung disease (CheckEPID): A Delphi-based consensus.
Calvin Lamas M; (...); Ventayol Bosch P
Article. 10.1016/j.farma.2023.06.010. 2023
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
Elevating the Standard of Care for Patients with Psoriatic Arthritis: 'Calls to Action' from a Multistakeholder Pan-European Initiative.
Verbinnen I; (...); Helliwell PS
Article. 10.1007/s40744-024-00664-3. 2024
Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis
Dobao, PD; (...); Puig, L
Article. 10.1111/jdv.15600. 2019
Hereditary angioedema in Spain: medical care and patient journey.
Caballero, Teresa; (...); Zamora, Carolina
Article. 10.1186/s13023-024-03182-1. 2024
Importance of adherence to treatment with direct-acting antivirals in hepatitis C.
Monte-Boquet E; (...); Ventayol P
Article. 10.1016/S0210-5705(20)30183-7. 2019
Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus Between Hospital Dermatologists and Pharmacists.
Herranz-Pinto P; (...); Tortajada Goitia B
Practice Guideline. 10.1016/j.ad.2023.04.019. 2023
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
Inhaled aztreonam lysine in the management of Pseudomonas aeruginosa in patients with cystic fibrosis: real-life effectiveness.
Jimenez-Lozano, Ines; (...); Alvarez-Fernandez, Antonio
Article. 10.1136/ejhpharm-2023-003937. 2023
Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey
Marin-Jimenez, I; (...); Monte-Boquet, E
Article. 10.7399/fh.11662. 2021
Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey.
Marín-Jiménez I; (...); Monte-Boquet E
Article. 10.7399/fh.11662. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
Oral Ribavirin for Treatment of Respiratory Syncytial Virus in Lung Transplantation Recipients.
Martin-Cerezuela, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1016/j.transproceed.2021.08.037. 2021
Patient-reported outcome measures in severe asthma: an expert consensus.
Martínez-Moragón E; (...); Sánchez-Cuellar S
Article. 10.1080/02770903.2023.2297372. 2023
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
Pilot evaluation of home delivery programme in haemophilia
Megias-Vericat, JE; (...); Poveda-Andres, JL
Article. 10.1111/jcpt.12718. 2018
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Aguas Peris M; (...); Nos, P
Article. 10.1097/MIB.0000000000001182. 2017
Spanish Society of Hospital Pharmacy Position Statement on Telepharmacy: Recommendations for its implementation and development
Morillo-Verdugo, R; (...); Delgado-Sanchez, O
Article. 10.7399/fh.11515. 2020
Telematic Interview in Telepharmacy: a comprehensive guide for pharmacotherapeutic follow-up and and informed drug delivery.
Barbadillo-Villanueva S; (...); Monte-Boquet E
Article. 10.1016/j.farma.2024.04.008. 2024
Telematic interview in telepharmacy: consensus document for farmacotherapeutic monitoring and informed drug delivery.
Barbadillo-Villanueva S; (...); Monte-Boquet E
Article. 10.1016/j.farma.2024.01.006. 2024
TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis.
Mercadal-Orfila G; (...); Herrera-Pérez S
Article. 10.3389/fmed.2024.1465725. 2024
Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice
Sahuquillo-Torralba, A; (...); Estrada, RB
Article. 10.1016/j.ad.2018.10.031. 2020